Biopharma 2018: Growth At A Reasonable Cost (GARC) [Seeking Alpha]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Seeking Alpha
Summary I maintain that the prospects for the biopharmaceutical industry are extremely favorable, driven by new drug discovery in oncology, hematology and inflammatory diseases. However, the stock valuations do not seem to reflect the prospects, with the above listed GARC (Growth At a Reasonable Cost) stocks trading at a blended P/E of 15x (which is below the overall stock market multiple). Gilead ( GILD ) reset Hepatitis C revenue expectations earlier this year to approximately 18% of the corporate total. With this appropriate forecast reduction, focus is now on the HIV franchise and the pipeline, both of which are promising. Regarding the former, Q2 2018 revenues of $3.7 billion increased by 13% and represented 66% of the corporate total (versus 46% in the prior year quarter). US Biktarvy sales were $183 million, and it is already the top regimen for switch patients, and according to management, it will achieve that position for treatment-naive patients. Descovy (FTC
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- Robbins LLP Reminds Investors of Bluebird Bio, Inc. to Contact the Law Firm for Information About the Class Action Against BLUEGlobeNewswire
- bluebird bio Announces Receipt of Expected Notice from NasdaqBusiness Wire
- bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 4/26/24 - Form 8-K
- 4/16/24 - Form 8-K
- 4/10/24 - Form SC
- BLUE's page on the SEC website